4Q and full-year 2021
Financial results

4Q 2021 NYSE: MRK

Worldwide sales GAAP EPS Non-GAAP EPS
$13.5 billion $1.51 $1.80

Anticipates full-year 2022 worldwide sales to be between $56.1 billion and $57.6 billion

Expects full-year 2022 GAAP EPS to be between $5.76 and $5.91; expects Non-GAAP EPS to be between $7.12 and $7.27

Key growth drivers

Oncology

KEYTRUDA® (pembrolizumab) Higher sales and continued uptake globally

Lynparza® (olaparib) + AstraZeneca

LENVIMA® (lenvatinib) + Eisai

Vaccines

GARDASIL® (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant) + GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)

Growth driven by strong global demand, particularly in China, which also benefitted from increased supply

Hospital Acute Care

bridion® (sugammadex 160 mg/amp.) Growth driven by higher demand globally

Animal Health

Growth driven by higher sales of companion animal products across geographies and species

“Our business achieved strong revenue and earnings growth this quarter and for the full year. Throughout 2021, we invested in the discovery, development, production and commercialization of medicines and vaccines, furthering the sustainability of our business.

We enter 2022 with strong momentum and are moving with speed to bring forward innovations that address critical unmet needs and contribute to global health. This remains at the core of our strategy, and why we are focused on benefitting the patients we serve, and in turn creating long-term value for our shareholders.”

Rob Davis
Chief Executive Officer and President

Creating long-term value for patients, employees and shareholders

See investors.merck.com for Merck’s full 4Q earnings release issued February 3, 2022, the associated webcast presentation, forward-looking statement, definitions of non-GAAP measures and reconciliations to the most closely related GAAP measure.